You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nanotechnology Enabled Temporomandibular Joint(TMJ)Prosthesis
SBC: VISTA ENGINEERING, INC. Topic: NIDCRDESCRIPTION (provided by applicant): Temporomandibular Disorders (TMD) represent a collection of medical and dental conditions affecting the temporomandibular joint (TMJ) and/or the muscles of mastication, as well as contiguous tissue structures. For somepatients with severe TMJ degeneration, a prosthetic replacement may be required. However, long-term success and functioning of current implant d ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Dynamically Tunable Metamaterials
SBC: Aegis Technologies Group, LLC, The Topic: A09AT002The technology, theory and fabrication of metamaterials have seen impressive progress in the last few years, and various applied fields have benefited from the flexibility of electromagnetic response that metamaterials provide at microwaves, infrared (IR) and/or optical frequencies. Negative-refractive and zero-permittivity metamaterials have been proposed for breakthrough novel applications in m ...
STTR Phase II 2011 Department of DefenseArmy -
Continuous monitoring of anti-fibrinolytic therapy in cardiovascular surgery
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while effective i ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health